Blog

Interested in recent clinical trial news and information on clinical trial services?

Keep up to date with our blogs.

Your Clinical Supply Chain – 4 Small Things That Can Have a Huge Impact

June 2017

Small changes can have a big impact on the overall success of a clinical trial, having a significant effect on the clinical supply chain and even putting it at risk. Here are 4 factors that can have a knock-on effect on your clinical supply chain. Delays in Manufacture, Procurement and/or Packaging It can be frustrating […]

View full article

FDA Approval of Renflexis, a Biosimilar to Remicade

June 2017

As of the 24th April 2017, the US Food and Drug Administration has approved Samsung Bioepis’ biosimilar version of Remicade (infliximab). The Biologics License Application (BLA) for the infliximab biosimilar candidate, Renflexis (SB2), was submitted to the FDA in May 2016. Infliximab is a chimeric monoclonal antibody administered intravenously, that is used for treating several […]

View full article

Complex Drug Products and their Generic Counterparts

May 2017

At the New York Academy of Sciences’ symposium on Equivalence of Complex Drug Products: Scientific and Regulatory Challenges, regulatory officials described how agencies approach evaluating complex generics for marketing approval. In 2015, almost 90% of prescriptions in the United States were for generics, according to the Generic Pharmaceutical Association. However, there are certain complex drug […]

View full article

Filgrastim Biological Shows Similar Efficacy to Originator

May 2017

A clinical study comparing two formulations of filgrastim for controlling chemotherapy-induced neutropenia has shown that the efficacy and safety profile of the test drug were similar to those of the originator product. Neutropenia is one of the most common chemotherapy-related adverse events, and in severe cases, places patients at high risk of serious infection with […]

View full article

The Importance of Detecting Counterfeit Medicines

April 2017

False medicines can present a huge health risk to the public. As well as potentially damaging the reputations of pharmaceutical companies, they can disrupt comparator sourcing and clinical trials services. The number of illegitimate and counterfeit medicines across the globe is becoming increasingly concerning, as they have even been appearing in the legitimate medical supply […]

View full article